Latest research on Fesoterodine

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Latest findings

With the diagnosis of OAB, Group 1 (n=60) received 5 mg solifenacin per day while Group 2 (n=59) received 4 mg Fesoterodine per day. [source, 2015]
The monthly drug costs of patients who received solifenacin and Fesoterodine were determined as US$21 in Group 1, and US$34 in Group 2. [source, 2015]
Various antimuscarinics, such as Oxybutynin, propiverine, Tolterodine, Trospium Chloride, Fesoterodine, and solifenacin were used in the treatment of OAB, and they have been widely used with their proven effectiveness and stability. [source, 2015]
There are some works in literature that evaluate the efficacy of Fesoterodine and solifenacin, which have become prominent in recent years. [source, 2015]
In a review article that compared Fesoterodine and Tolterodine, it has been reported that Fesoterodine is superior to Tolterodine due to its OAB symptoms. [source, 2015]
However, the rate of discontinuation of the drug due to side effects is more common in Fesoterodine rather than Tolterodine. [source, 2015]
Although in their study for comparison of Fesoterodine and Tolterodine, Du Beau et al21 found out that both drugs are similar in terms of efficacy, dry mouth and constipation symptoms were more commonly observed in the Fesoterodine group. [source, 2015]
A study in which placebo and Fesoterodine have been compared in patients that gave sub-optimal response to the Tolterodine, puts forward that treatment efficacy of Fesoterodine is fair, and can be well-tolerated in terms of anticholinergic side effects.22 [source, 2015]
In the literature, 4 mg/day was proposed for Fesoterodine as a starting dose, and the maximum dose was reported as 8 mg/day. [source, 2015]
While evaluating the side effects in our study, it was found out that the discontinuation of drugs due to the side effects was more common in treatment with Fesoterodine, while the use of both drugs did not cause a significant difference for patients with dry mouth and constipation symptoms ( [source, 2015]